KCNJ11 mutations are common in both TNDM and PNDM and are associated with a higher birth weight compared with patients with 6q24 abnormalities. Patients with TNDM should be screened for abnormalities in glucose metabolism in adult life.

2543 Background: High levels of myeloid-derived suppressor cells (MDSCs) seem a negative prognostic factor in advanced breast cancer (ABC) patients (pts). Preclinical studies suggest an immunomodulatory effect of some classical anti-tumor agents through alteration of MDSCs homeostasis. We analyzed the association of MDSCs and clinical evolution of ABC pts, taking into account the systemic treatment (tx) modulation of MDSCs levels in pts from two studies (“A”: GEICAM/2015-04 PANGEA-BREAST, NCT03025880 “Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC”, and “B”: PI-0502-2014 “Peripheral blood analyses of immune response induced by 1st line tx of ABC according to clinical guidelines”). Methods: MDSCs (CD33+ CD11b+) levels were determined by flow-cytometry in peripheral blood samples at three time points (basal, at cycles 3 and 6) from: 39 HER2-negative heavily pretreated pts from study “A”, 43 non-pretreated pts (all subtypes) from study “B” and 20 women from a healthy cohort (HC), with no cancer diagnosis. MDSCs levels from the different cohorts were compared and correlated with pts with Clinical Benefit (CB: partial/complete response + disease stabilization) vs pts with Progressive Disease (PD). Results: Tx response was assessed in 33 pts (85%) from study “A” and 39 pts (91%) from study “B”. CB was observed in 11 pts (28%) from study “A” and in 34 (79%) from study “B” while PD was observed in 22 pts (56%) from study “A” and in 5 (12%) from study “B”. Basal MDSCs levels were significantly higher in ABC pts (studies “A”+”B”) than in HC (15.95 vs 0.81 cells/µl, p = 0.009). At cycle 6, MDSCs were considerably lower in pts with CB vs DP (2.90 vs 13.75 cells/µl, p < 0.001). This decrease was more pronounced in study “B” than in study “A” pts (p < 0.001 vs p = 0.074, respectively), probably due to differences in number of events, tumor subtypes and tx between both studies. Conclusions: Our results suggest that ABC pts show alterations in MDSCs and that their decrease along tx may have a positive predictive value, highlighting the importance that immune-competent status may play in the evolution of ABC. MDSCs may represent a target for therapeutic purposes in ABC.

No abstract

This study aimed to analyze changes in the level of functional mobility (FM) between patients with solid tumors discharged from intensive care units (ICU) and hospital discharge and the possible factors associated with FM recovery. This is a retrospective cohort study based on the analysis of medical records of patients with solid tumors who were discharged from an oncology ICU from January 1, 2018 to February 28, 2020. The primary outcome was the change in FM after ICU discharge, considering the difference between the final score at ICU discharge and the final score at hospital discharge, estimated by the ICU Mobility Scale (IMS). The association between continuous variables and outcomes was performed by univariate linear regression analysis. In total, 65 patients with a median age of 61.4 years (interquartile range - IQR 54-69) were included. The mean length of hospital stay after discharge from the ICU was 19.0 days (±24.04). The mean IMS score at ICU discharge was 2.62 (±2.56) and the mean IMS score at hospital discharge was 6.08 (±3.26). Patients who underwent surgery to treat the primary tumor had a score 1.89 higher compared to those who did not undergo surgery (p=0.048). Therefore, we observed improvement in FM in patients with solid tumors between ICU discharge and hospital discharge, and patients who underwent surgery showed better FM.

No abstract

No abstract

No abstract

No abstract